In this conversation, Tina Eden, R.N., CEO of Virginia Gay Hospital, and Jacinda Bunch, Ph.D., R.N., assistant professor at ...
Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal ...
First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries– Investigator-Initiated (IIT) funded pancreatic and ...
| Servier is committing to rare neurology for the long term, using focused science and strategic collaborations to bring new ...
Challenges remain, like regulatory hurdles and funding, but our team's grit and your support as shareholders make me ...
Chris R. Alabiad, MD: There wasn’t one single national rule change in 2025 that transformed residency training overnight.
Insilico Medicine (“Insilico”), a world-leading artificial intelligence (AI)-driven drug discovery company, today announced a ...
Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment ...
The company also announced the appointment of Han Lee, Ph.D., as co-chief executive officer (CEO), and the U.S. Food and Drug ...
R & R Health announces new sober living and outpatient addiction treatment services in Redondo Beach to support lasting, real world recovery. Our sober living and outpatient programs give people the ...
MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License ...
Zymeworks (ZYME) posts strong Phase 3 Ziihera data in HER2+ GEA and eyes up to $440M in milestones plus royalties—read the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback